Ten-Year Experience with a Transapical Approach for Transcatheter Aortic and Mitral Valve Implantation.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS

ACS Applied Bio Materials Pub Date : 2024-06-29 DOI:10.3390/jcdd11070201

Antonella Galeone, Fabiola Perrone, Gabriele Pesarini, Flavio Luciano Ribichini, Renato Di Gaetano, Giovanni Battista Luciani, Francesco Onorati

{"title":"Ten-Year Experience with a Transapical Approach for Transcatheter Aortic and Mitral Valve Implantation.","authors":"Antonella Galeone, Fabiola Perrone, Gabriele Pesarini, Flavio Luciano Ribichini, Renato Di Gaetano, Giovanni Battista Luciani, Francesco Onorati","doi":"10.3390/jcdd11070201","DOIUrl":null,"url":null,"abstract":"Background: The transfemoral approach represents the optimal access for TAVI due to its low invasiveness; however, up to 10-15% of TAVI candidates are considered unsuitable for femoral access because of significant peripheral vascular disease and need alternative access.Methods: This is a single-center retrospective observational study including all consecutive adult patients undergoing transcatheter procedures through a TA approach from March 2015 to April 2024.Results: 213 patients underwent transcatheter aortic or mitral valve implantation through a TA approach and were enrolled in this study. The mean age of the patients was 79.5 ± 5.7 years, and 54% of the patients were males. The mean Euroscore II was 7.9 ± 6.4%. One-third of the patients had previous cardiac surgery. The overall mean survival time was 5.3 ± 0.3 years. Nine (4%) patients developed infective endocarditis (IE) during the follow-up.Conclusions: The transapical approach for transcatheter procedures is a safe and effective procedure for patients unsuitable for TF access with low periprocedural mortality and a low rate of post-procedural complications when performed by experienced surgeons and cardiologists.","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":"11 7","pages":""},"PeriodicalIF":4.6000,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11277261/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/jcdd11070201","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The transfemoral approach represents the optimal access for TAVI due to its low invasiveness; however, up to 10-15% of TAVI candidates are considered unsuitable for femoral access because of significant peripheral vascular disease and need alternative access.

Methods: This is a single-center retrospective observational study including all consecutive adult patients undergoing transcatheter procedures through a TA approach from March 2015 to April 2024.

Results: 213 patients underwent transcatheter aortic or mitral valve implantation through a TA approach and were enrolled in this study. The mean age of the patients was 79.5 ± 5.7 years, and 54% of the patients were males. The mean Euroscore II was 7.9 ± 6.4%. One-third of the patients had previous cardiac surgery. The overall mean survival time was 5.3 ± 0.3 years. Nine (4%) patients developed infective endocarditis (IE) during the follow-up.

Conclusions: The transapical approach for transcatheter procedures is a safe and effective procedure for patients unsuitable for TF access with low periprocedural mortality and a low rate of post-procedural complications when performed by experienced surgeons and cardiologists.

查看原文本刊更多论文

采用经心尖切口进行经导管主动脉瓣和二尖瓣植入术的十年经验。

背景：经股动脉入路由于创伤小，是TAVI的最佳入路；然而，高达10%-15%的TAVI候选者由于严重的外周血管疾病而被认为不适合股动脉入路，需要其他入路：这是一项单中心回顾性观察研究，包括2015年3月至2024年4月期间通过TA入路接受经导管手术的所有连续成年患者。结果：213名患者通过TA入路接受了经导管主动脉瓣或二尖瓣植入术，并被纳入本研究。患者的平均年龄为（79.5±5.7）岁，54%为男性。平均欧洲评分 II 为 7.9 ± 6.4%。三分之一的患者曾接受过心脏手术。总平均存活时间为 5.3 ± 0.3 年。9名（4%）患者在随访期间患上了感染性心内膜炎（IE）：结论：对于不适合接受经导管介入手术的患者来说，经心尖介入经导管手术是一种安全有效的手术，如果由经验丰富的外科医生和心脏病专家实施，其围手术期死亡率低，术后并发症发生率低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ACS Applied Bio Materials Chemistry-Chemistry (all)

CiteScore

9.40

自引率

2.10%

发文量

464